Study of the Therapeutic Effects of Naohuan Dan and Idebenone in Treating Mild Cognitive Impairment With Kidney Deficiency and Phlegm Stasis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

64 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-05-01

Study Completion Date

2022-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study conducted a retrospective analysis of 64 patients with mild cognitive impairment of the kidney deficiency phlegm and stasis type who underwent treatment with Naohuan Dan combined with Idebenone. The patients' cognitive function was evaluated using the Mini-Mental State Examination (MMSE) and the Montreal Cognitive Assessment (MoCA) before and after treatment. Daily living abilities were assessed using the Activities of Daily Living (ADL) scale, depression status was evaluated using the Geriatric Depression Scale (GDS), and the severity of Traditional Chinese Medicine (TCM) syndrome was assessed using the TCM diagnostic scale. Peripheral blood from the patients was also collected for analysis of neuron-specific enolase (NSE) and inflammatory factors. The aim was to evaluate the safety and feasibility of using Naohuan Dan combined with Idebenone for the treatment of mild cognitive impairment of the kidney deficiency phlegm and stasis type.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prospective Cohort Study of Patients With Early Alzheimer's Disease Treated With Lecanemab

NCT06741553

Alzheimer Disease Mild Cognitive Impairment (MCI)

RECRUITING

Zydena on Cognitive Function of Alzheimer's Disease Patients

NCT01940952

Alzheimer's Disease

UNKNOWN PHASE3

The Clinical Study of Synaptic Plasticity-based Lencanumab for the Treatment of Early Alzheimer's Disease

NCT06871839

Alzheimer's Disease Lecanemab Functional Magnetic Resonance Imaging

RECRUITING

Technical R&D and Demonstration of Intelligent Medical Care in Alzheimer's Disease's Management

NCT05641480

Alzheimer Disease Subjective Cognitive Decline Mild Cognitive Impairment +1 more

RECRUITING NA

Efficacy and Safety Study of Shenwu Capsule

NCT01451749

Mild Cognitive Impairment

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mild Cognitive Impairment

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

The control group

The control group received Idebenone orally, at a dose of 30mg per time, three times a day, after meals for 12 consecutive weeks.

Idebenone

Intervention Type DRUG

The control group took Idebenone orally for 12 weeks.

The treatmen group

The treatment group received Naohuan Dan combined with Idebenone. At a dose of one per day, delivered with warm water in the morning and evening, and taken orally for 12 consecutive weeks.

Naohuan Dan and Idebenone

Intervention Type DRUG

The treatment group took Naohuan Dan combined with Idebenone for treatment. Naohuan Dan is a granular preparation taken once a day, while Idebenone is a tablet taken three times a day for a total of 12 weeks.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Idebenone

The control group took Idebenone orally for 12 weeks.

Intervention Type DRUG

Naohuan Dan and Idebenone

The treatment group took Naohuan Dan combined with Idebenone for treatment. Naohuan Dan is a granular preparation taken once a day, while Idebenone is a tablet taken three times a day for a total of 12 weeks.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis in accordance with both Chinese medicine and Western medicine.
* Age between 55 and 85 years, with no gender restrictions.
* A score between 21 and 26 on the Mini-Mental State Examination (MMSE), with 1 point for primary school education.
* Willingness to participate in the study and signing of the informed consent form.

Exclusion Criteria

* Patients with severely impaired heart, liver, kidney, or other organs functions.
* Patients with neurological diseases that affect brain function and cognitive impairment.
* Patients with severe depression or other mental illnesses.
* Patients with poor compliance or cooperation who were unable to complete the study according to the protocol.

Minimum Eligible Age

55 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No